Sukumar Nagendran Sells 260,047 Shares of Taysha Gene Therapies (NASDAQ:TSHA) Stock

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) insider Sukumar Nagendran sold 260,047 shares of the company’s stock in a transaction on Monday, December 1st. The stock was sold at an average price of $4.51, for a total value of $1,172,811.97. Following the sale, the insider owned 1,006,439 shares of the company’s stock, valued at $4,539,039.89. The trade was a 20.53% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Sukumar Nagendran also recently made the following trade(s):

• On Friday, November 28th, Sukumar Nagendran sold 110,125 shares of Taysha Gene Therapies stock. The shares were sold at an average price of $4.75, for a total value of $523,093.75.
• On Wednesday, September 10th, Sukumar Nagendran sold 200,000 shares of Taysha Gene Therapies stock. The stock was sold at an average price of $3.23, for a total value of $646,000.00.

Taysha Gene Therapies Price Performance

NASDAQ:TSHA traded down $0.31 during trading hours on Monday, hitting $4.43. The company’s stock had a trading volume of 2,376,681 shares, compared to its average volume of 3,725,400. Taysha Gene Therapies, Inc. has a twelve month low of $1.05 and a twelve month high of $5.51. The company has a debt-to-equity ratio of 0.23, a current ratio of 10.48 and a quick ratio of 10.48. The stock has a fifty day simple moving average of $4.40 and a 200-day simple moving average of $3.32. The company has a market capitalization of $1.21 billion, a P/E ratio of -13.42 and a beta of 1.06.

Taysha Gene Therapies (NASDAQ:TSHA) last posted its earnings results on Tuesday, November 4th. The company reported ($0.09) EPS for the quarter, hitting analysts’ consensus estimates of ($0.09). Taysha Gene Therapies had a negative net margin of 1,144.97% and a negative return on equity of 67.26%. On average, analysts anticipate that Taysha Gene Therapies, Inc. will post -0.35 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities analysts recently commented on TSHA shares. JMP Securities set a $8.00 price objective on shares of Taysha Gene Therapies in a research note on Wednesday, November 5th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Taysha Gene Therapies in a report on Tuesday, November 25th. Wells Fargo & Company raised their price objective on Taysha Gene Therapies from $7.50 to $8.00 and gave the company an “overweight” rating in a report on Wednesday, August 13th. Needham & Company LLC restated a “buy” rating and set a $10.00 price objective on shares of Taysha Gene Therapies in a research report on Friday, October 17th. Finally, Chardan Capital reaffirmed a “buy” rating and issued a $12.00 target price on shares of Taysha Gene Therapies in a report on Wednesday, November 5th. One analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $10.30.

Hedge Funds Weigh In On Taysha Gene Therapies

Hedge funds have recently modified their holdings of the business. Vanguard Group Inc. increased its holdings in Taysha Gene Therapies by 17.9% in the third quarter. Vanguard Group Inc. now owns 12,849,613 shares of the company’s stock valued at $42,018,000 after purchasing an additional 1,955,486 shares during the period. Octagon Capital Advisors LP lifted its holdings in Taysha Gene Therapies by 17.7% during the 2nd quarter. Octagon Capital Advisors LP now owns 12,592,500 shares of the company’s stock worth $29,089,000 after buying an additional 1,892,500 shares during the period. Jefferies Financial Group Inc. grew its position in shares of Taysha Gene Therapies by 4,105.3% in the 2nd quarter. Jefferies Financial Group Inc. now owns 10,313,733 shares of the company’s stock valued at $23,825,000 after buying an additional 10,068,479 shares during the last quarter. Vestal Point Capital LP increased its stake in shares of Taysha Gene Therapies by 83.3% in the third quarter. Vestal Point Capital LP now owns 5,500,000 shares of the company’s stock valued at $17,985,000 after buying an additional 2,500,000 shares during the period. Finally, Polar Capital Holdings Plc raised its position in shares of Taysha Gene Therapies by 5.9% during the third quarter. Polar Capital Holdings Plc now owns 5,293,879 shares of the company’s stock worth $17,311,000 after acquiring an additional 293,879 shares during the last quarter. Institutional investors and hedge funds own 77.70% of the company’s stock.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.